HBM Partners is a Swiss healthcare investor with over $2.5 billion assets under management. HBM Partners was founded in 2001 with the goal to invest in emerging private and public biopharma and other healthcare companies. HBM Partners is regulated by FINMA and manages SIX listed HBM Healthcare Investments (www.hbmhealthcare.com) and further specialized public and private equity funds.

HBM Partners has a team of over 20 experienced professionals to source, analyze and engage in investments in biopharma, medical devices and diagnostics industries. HBM’s investments in private biopharma and healthcare companies have resulted in significant value creation with more than 100 trade sales and IPOs. In private portfolio companies HBM takes an active role and assumes entrepreneurial responsibility together with the management team.

HBM is actively looking for further investment opportunities, mainly in later-stage product/drug development and growth companies (including spin-offs and small buyouts). New investments range from $10 million to $50 million. Preferred geographies are Western Europe, USA, India and China.